Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis by Bettinardi, A. et al.
1997 89: 902-909
 
 
 
 
 
Antonio Correra and Luigi D. Notarangelo 
Alessandra Bettinardi, Duilio Brugnoni, Eugenia Quiròs-Roldan, Alberto Malagoli, Stefania La Grutta,
 
Lymphoproliferative Syndrome: A Molecular and Immunological Analysis 
Missense Mutations in the Fas Gene Resulting in Autoimmune
 http://bloodjournal.hematologylibrary.org/cgi/content/full/89/3/902
Updated information and services can be found at: 
 (3530 articles)Immunobiology 
 collections: BloodArticles on similar topics may be found in the following 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at: 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints
Information about ordering reprints may be found online at: 
 http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl
Information about subscriptions and ASH membership may be found online at: 
. Hematology; all rights reservedCopyright 2007 by The American Society of 
DC 20036.
by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly
 
 
 
 
 For personal use only. by on August 7, 2008. www.bloodjournal.orgFrom 
Missense Mutations in the Fas Gene Resulting in Autoimmune
Lymphoproliferative Syndrome: A Molecular and Immunological Analysis
By Alessandra Bettinardi, Duilio Brugnoni, Eugenia Quiro`s-Roldan, Alberto Malagoli, Stefania La Grutta,
Antonio Correra, and Luigi D. Notarangelo
Programmed cell death (or apoptosis) is a physiological pro- features including splenomegaly and lymphadenopathy, but
cess essential to the normal development and homeostatic only one developed severe autoimmune manifestations. In
maintenance of the immune system. The Fas/Apo-1 receptor all three siblings, we demonstrated the presence of anergic
plays a crucial role in the regulation of apoptosis, as demon- CD3"CD4ÏCD8Ï (double negative, [DN]) T cells; moreover, a
strated by lymphoproliferation in MRL-lpr/lpr mice and by chronic lymphocyte activation was found, as demonstrated
the recently described autoimmune lymphoproliferative by the presence of high levels of HLA-DR expression on pe-
syndrome (ALPS) in humans, both of which are due to muta- ripheral CD3" cells and by the presence of high levels of
tions in the Fas gene. We describe a novel family with ALPS serum activation markers such as soluble interleukin-2 re-
in which three affected siblings carry two distinct missense ceptor (sIL-2R) and soluble CD30 (sCD30).
mutations on both the Fas gene alleles and show lack of q 1997 by The American Society of Hematology.
Fas-induced apoptosis. The children share common clinical
P More recently, human equivalents of the murine lpr/lpr phe-notype have been reported in eight patients from seven unre-ROGRAMMED CELL DEATH (or apoptosis) is a keymechanism of cellular homeostasis in the immune sys-
tem, both in the thymus (resulting in deletion of autoreactive lated pedigrees16,17; lack of apoptosis was observed in vitro,
upon addition of agonistic antibodies to Fas. In all cases,thymocytes), and in the periphery, where activation-induced
cell death (AICD) plays a crucial role in the extinction of the the clinical features included early-onset splenomegaly and
lymphadenopathy with accumulation of CD3/ DN T cellsimmune response to foreign antigens and in the peripheral
deletion of autoreactive lymphoid cells.1-3 (mainly expressing the AB form of the T-cell receptor
[TCR]); in addition, a variable degree of autoimmune mani-Fas/Apo-1 (CD95) and Fas ligand (FasL), two counter-
receptors expressed on the surface of activated lymphocytes, festations were present. In all cases reported so far, patients
had heterozygous mutations in the Fas gene, which in somehave been recognized as functional molecules in AICD.4,5
Cross-linking of Fas with specific antibodies,6,7 with cells cases led to production of dominant negative Fas mutants
interfering with the function of wild-type Fas molecules. Inexpressing Fas-ligand (FasL), or with purified soluble FasL8,9
leads to apoptosis, with appearance of characteristic cyto- two pedigrees (patients 2 and 3 from Rieux-Laucaut et al16
and family 3 from Fisher et al17), the investigators postulatedplasmic and nuclear condensation and DNA fragmentation.
A characteristic motif (the so-called death domain) in the a digenic disorder, because they found defective, but not
abolished, Fas-induced apoptosis in the parent who did notintracytoplasmic tail of Fas, sharing homology with a similar
sequence of the closely related tumor necrosis factor-recep- carry mutations in the Fas gene. Based on these observations,
the pattern of inheritance of the human Fas defect appearstors (TNF-R), is involved in the apoptotic signal, as indicated
by naturally occurring and artificially created Fas mu- to differ from that reported in MRL-lpr/lpr mice.
We describe a novel family with autoimmune lymphopro-tants.10,11 Murine models of defective Fas function include
the MRL-lpr/lpr and the lprcg mice, both of which are liferative syndrome (ALPS) in which three affected siblings
carry two distinct missense mutations in the Fas gene andcharacterized by massive lymphadenopathy and spleno-
megaly, with accumulation of a unique population of show a lack of Fas-induced apoptosis. No clinical or immu-
nological defect and no evidence of defective Fas functionCD3/TCRAB/CD40CD80 (referred to as double negative
[DN], T cells) in the periphery.12,13 In addition, both MRL- was identified in the parents, each of whom carried one of
the two mutant alleles. Extensive family history failed tolpr/lpr and lprcg mice show an increased occurrence of auto-
immune manifestations, whose severity is highly influenced show other affected relatives. This is the first example of a
human autosomal recessive ALPS due to single amino acidby the genetic background.14,15
Occurrence of lymphoproliferation in murine models of substitution in the Fas protein.
Fas defect is inherited as an autosomal recessive trait.12,13
MATERIALS AND METHODS
Case reports. A pedigree with three male siblings (III,3-5) withFrom Consorzio per le Biotecnologie, Servizio di Immunologia
Clinica, Clinica Pediatrica, Spedali Civili di Brescia, Brescia; Clin- clinical features of ALPS is shown in Fig 1. As shown in Table
1, these children shared the clinical features of severe, early-onsetica Pediatrica, Universita` di Palermo, Palermo; and Divisione di
Pediatria, Ospedale S.S. Annunziata, Napoli, Italy. splenomegaly and lymphadenopathy, as well as the presence of auto-
antibodies, which were associated with autoimmune hemolytic ane-Submitted July 10, 1996; accepted September 13, 1996.
Supported in part by Telethon (Rome, Italy) Grant No. A.42 to mia and thrombocytopenia in patient N.F. One of the patients (M.F.)
developed hypergammaglobulinemia, with increased IgG and IgAL.D.N.
Address reprint requests to Duilio Brugnoni, MD, Servizio di serum levels. The parents were unrelated and showed no clinical or
immunological abnormalities, or had they ever developed adenopa-Immunologia Clinica, Spedali Civili, 25123 Brescia, Italy.
The publication costs of this article were defrayed in part by page thy or splenomegaly in childhood. A detailed clinical history and
physical examination was obtained in all relatives, and none of themcharge payment. This article must therefore be hereby marked
‘‘advertisement’’ in accordance with 18 U.S.C. section 1734 solely to appeared to have developed lymphadenopathy, splenomegaly, or
autoimmunity at any time in their life. Subject II,5 had died at 26indicate this fact.
q 1997 by The American Society of Hematology. years of age of osteosarcoma; subject III,12 presents with mental
and motor retardation as the result of perinatal asphyxia.0006-4971/97/8903-0010$3.00/0
902 Blood, Vol 89, No 3 (February 1), 1997: pp 902-909
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(Beckman, Fullerton, CA) and the results were expressed as mean
cpm of triplicates { standard error of mean (SEM).
Immunofluorescence. Evaluation of lymphocyte surface mem-
brane expression was performed on heparinized whole blood samples
with the following MoAbs: fluorescein isothiocyanate (FITC)-conju-
gated OKT3 (CD3), FITC-OKT4 (CD4), FITC-OKT8 (CD8), FITC-
OKT11 (CD2), phycoerytrin (PE)-conjugated OKDR (HLA DR)
from Ortho, FITC-TCR alpha/beta (TCRAB), PE-Leu 28 (CD28),
Fig 1. Pedigree of a family with ALPS. Patients III,3, III,4, and III,5 PE-Leu11c (CD16), Leu-23 (CD69) from Becton Dickinson (Moun-
correspond to subjects SF, NF, and MF, respectively. tain View, CA), FITC-B4 (CD19) from Coulter Immunology (Hia-
leah, FL). For unconjugated MoAbs, an indirect immunofluorescence
method was applied using a FITC-affinity–purified goat antimouse
IgG antibody (Ortho).Evaluation of autoimmunity. Antinuclear antibodies (ANA)
For CD95 expression analysis, 2 1 105 PBMC were cultured inwere detected by indirect immunofluorescence using HEp-2 cells as
96-well flat-bottomed microtiter plates (Nunc, Roskilde, Denmark)substrate (Kallestad, Chaska, MN), and titers of at least 1:80 were
with PHA (1.2 mg/mL) in a final volume of 200 mL/w.considered positive. Anticardiolipin antibodies were measured in
After activation for 72 hours, cells were harvested, washed twopatients sera by enzyme-linked immunosorbent assay (ELISA), fol-
times with phosphate-buffered saline (PBS)-5% FCS, and incubatedlowing the method suggested by the International Standardization
for 30 minutes at 47C with a panel of different mouse monoclonalsWorkshop.18
to human CD95: CH11 antibody (Medical and Biological Labora-Cell preparation. Mononuclear cells from the patient and from
tories Co, Nagoya, Japan); DX2 antibody (Pharmingen, San Diego,the parents were separated from the peripheral blood by Ficoll-
CA); 7C11 antibody (from Robertson) and B.D29, B.E28, B.G27,Hypaque density gradient centrifugation and washed three times in
B.G30, B.G34, B.K14, B.L25 antibodies (from Cattin/Wijdenes),RPMI-1640 (GIBCO Laboratoires, Grand Island, NY).
provided through the 6th International Workshop and Conference onDepletion of CD4/ and CD8/ cells from peripheral blood mono-
Human Leukocyte Differentiation Antigens. Cells were then washednuclear cell (PBMC) was obtained using negative selection with
twice in PBS-FCS and incubated with FITC-affinity–purified goatCD40 and CD80 conjugated magnetic beads (Dynal, Oslo, Norway),
antimouse IgG antibody (Ortho).as recommended by the manufacturer; less than 3% of negatively
For CD40 ligand (CD40L) and CD69 expression analysis, 2 1selected PBMC expressed CD4 and CD8 after this procedure, as
105 CD4/CD8-depleted PBMC, or CD4/ plus CD8/ cells were cul-assessed by immunofluorescence analysis. This population was en-
tured in 96-well flat-bottomed microtiter plates (Nunc) with PMAriched in CD3/CD40CD80 cells (51%) and was, therefore, used in
(5 ng/mL; Sigma, St Louis, MO) plus ionomycin (500 ng/mL;experiments of proliferation, CD40L expression, and T-cell receptor
Sigma) in a final volume of 200 mL/w.beta variable chain (TCRBV) mRNA analysis.
After activation for 16 hours, cells were harvested, washed twoFor the same analysis, CD4/ and CD8/ cells were further purified
times with PBS-5% FCS, and incubated for 30 minutes at 47C,from PBMC by positive selection with CD4- and CD8-coated beads
respectively, with 50 mL of antihuman CD40L specific mouse MoAb(Dynal): over 96% of positively selected cells were CD4/ or CD8/.
(TRAP1, kindly provided by Dr R. Kroczek, Robert Koch Institute,Cell cultures. All experiments were performed in complete me-
Berlin, Germany); cells were then washed twice in PBS-FCS anddium supplemented with 10% heat-inactivated fetal calf serum
incubated with FITC-affinity–purified goat antimouse IgG antibody(FCS), 1% glutamin and antibiotics. Proliferative responses were
(Ortho).measured in triplicates of 200 mL containing 1 1 105 total or CD4/
After two washes in PBS-FCS, samples were analyzed with aCD8-depleted PBMC using various combinations of the following
flow cytometer equipped with an argon-ion laser (488 nm; Cytoronstimulating agents: immobilized anti-CD3 monoclonal antibody
Absolute; Ortho), using the ABS software. Gates were selected on(MoAb), 200 ng/mL (OKT3; Ortho, Raritan, NJ), with or without
lymphoid cells as determined by forward and right-angle scatterinterleukin-2 (IL-2), 20 U/mL (Biosource International, Camarillo,
properties; dead cells were excluded by setting an appropriate thresh-CA); phytohemoagglutinin (PHA), 1.2 mg/mL (Irvine Scientific,
old trigger on the low forward light scatter parameter, and nonspe-Santa Ana, CA); Staphylococcus aureus Enterotoxin B (SEB; 500
cific staining was assessed using FITC-conjugated nonimmuneng/mL; Serva Feinbiochemica, Heidelberg, Germany). After 72
mouse IgG (Coulter). Data were acquired and stored in list mode.hours of culture at 377C, 5% CO2, the cells were pulsed overnight
Fluorescence analysis was performed on a log scale.with 1 mCi (3H)-thymidine and were harvested subsequently. Incor-
porated radioactivity was measured by liquid scintillation counting Soluble activation markers determination. Serum levels of sIL-
Table 1. Patients’ Features
Features Patient M.F. Patient N.F. Patient S.F.
Age 5 yr 11 mo 13 yr 8 mo 15 yr 4 mo
Splenomegaly /// /// //
(age at onset) 1 mo 1 yr 6 mo 1 yr
Lymphoadenopathy /// // //
IgG (g/L) 41.8 12.0 13.6
IgA (g/L) 5.5 2.1 2.9
IgM (g/L) 1.4 0.8 1.2
Autoimmunity:
Clinical features None AHA, thrombocytopenia None
Autoantibodies ANA, APL APL, APA ANA, APL
Abbreviations: AHA, autoimmune hemolytic anemia; ANA, antinuclear antibody; APL, antiphospholipid antibody; APA, antiplatelet antibody.
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2R and sCD30 were evaluated with a commercial ELISA-kit (respec- by adding at the 5* end an EcoRI and HindIII restriction site. The
PCR product is about 1,100 bp long. The amplification was per-tively, T Cell Diagnostics, Cambridge, MA and Dako, Glostrup,
Denmark), as recommended by the manufacturer. formed for 35 cycles under the following conditions: denaturation
at 937C for 60 seconds, annealing at 527C for 60 seconds, andApoptosis assay. For the apoptosis assay, after activation for 2
days with PHA (1.2 mg/mL) and 5 days with IL-2 (20 U/mL), PBMC extension at 727C for 120 seconds. The last cycle extension was
performed at 727C for 10 minutes.(2 1 106/mL) were transferred to a 96-well culture plate coated with
MoAb CH11 at the indicated concentration, or supplemented with For TCR repertoire analysis, 1 mg of RNA from both CD4/ CD8/
and TCRAB/ CD40 CD80 lymphocyte subpopulation of the onlydexamethasone 1005 mol/L.
Cells were washed after 24 hours and the percentage of hypodip- child studied (M.F.) was also used to synthesize the first strand of the
TCRB chain-specific cDNA using the RiboClone cDNA Synthesisloid nuclei (less than 2N DNA content) was determined with a slight
modification of the method of Nicoletti et al.19 System and a primer specific for TCRBC1 and TCRBC2 human
genes (bcDNA: 5* GGG CTG CTC CTT GAG GGG CTG CGGBriefly, 1 1 106 lymphocytes were fixed in 1 mL of cold 70%
ethanol at 47C for 20 minutes. Cells were then washed, incubated at 3*). The cDNA was then subjected to enzymatic amplification using
a second TCRBC primer (bAI: 5* CCC ACT GTG CAC CTC CTTroom temperature for 1 minute with RNase (0.5 mg/mL; Boehringer
GmbH, Mannheim, Germany), for 15 minutes with propidium iodide CC 3*) and a TCRBV degenerated primer (Vbd: 5* T(GT)T(ACT)
(CT)TGGTA(CT)(AC)(AG)(AT)CA 3*), which was designed to am-(100 mg/mL; Sigma), and immediately analyzed. The correct thresh-
old was selected experimentally using the model system of apoptosis plify TCRB chain rearrangements containing virtually all the known
human TCRBV genes.21 The PCR products are about 430 bp long;induced in murine thymocytes by 72 hours culture with dexametha-
sone 1007 mol/L. Apoptotic cell nuclei, easily distinguishable from they contain one half of the V region gene and extend through
the V-D-J junction to the TCRBC region. The amplification wasdebris owing to the condensation of nuclear chromatin, emitted red
fluorescence in the RD-FL channels 46-146. As there was no overlap performed under the following conditions: 40 cycles of 937C for 60
seconds, 527C for 60 seconds, and 727C for 60 seconds. The speci-between apoptotic nuclei and debris, the small percentage of residual
low-fluorescence detritus (1% in normal cells) was eliminated by ficity of the total amplified products was analyzed using the pre-
viously described colorimetric method and biotynilated TCRBV-gating at channel 45 of the red fluorescence scale. All measurements
were performed with the same instrument setting. specific probes.22 The relative percentage of expression of each of
the TCRBV segments analyzed was calculated by normalizing theThe percent of hypodiploid cells at each CH11 concentration was
calculated as follows: (% of hypodiploid cells from wells with MoAb optical density (OD) value of each individual TCRBV segment
(OD[i]) with respect to the sum of the OD values of all 26 TCRBV0 % of hypodiploid cells from wells without MoAb)/100 0 % of
hypodiploid cells from wells without MoAb. chains.
Preparation of genomic DNA and amplification of target FASMoreover, the percent of hypodiploid cells induced by dexametha-
sone was calculated as follows: (% of hypodiploid cells from wells sequences by PCR. Amplification of the genomic fragment encom-
passing the mutation in exon 9 was obtained with the followingwith dexamethasone 0 % of hypodiploid cells from wells without
dexamethasone)/1000% of hypodiploid cells from wells with dexa- primers: F5*-CTGAAGTACTATAAAAGAGAAAT-3*; R5*-GTC-
ATTCTTGATCTCATCTATTTTGGCT-3*, whereas the genomicmethasone.
Preliminary experiments on healthy subjects failed to show sig- region encompassing the mutation in exon 4 was amplified with
these primers: F5*-TAACTAATAGTTTCCAAACTG-3*; R5*-TGT-nificant differences in either Fas-mediated or dexamethasone-in-
duced apoptosis between children and adults. TTTAATCAGAGAAAGAC-3*. For PCR amplification, the follow-
ing conditions were used: 30 cycles at 937C for 30 seconds, 507CDNA extraction. High molecular weight DNA was isolated from
proteinase-K–treated peripheral blood leukocytes by salting-out in for 30 seconds, 727C for 30 seconds, and 947C for 30 seconds, 597C
for 60 seconds, 727C for 60 seconds for mutation in the exon 4 andmini scale, as previously described in detail.20 Briefly, erythrocytes
were lysed by the addition of 2 mL red blood cell lysis buffer (10 9, respectively. The last cycle extension was performed at 727C for
10 minutes.mmol/L Tris-HCl, pH 7.6; 5 mmol/L MgCl2; 10 mmol/L NaCl) to
1 mL EDTA blood; leukocytes were spun down (13,000 rpm for 1 The 169-bp segment surrounding the mutation in exon 4 was
trimmed to 56 bp by digestion with HpaII to facilitate mutationminute); the pellet was washed once with H2O (13,000 rpm for 1
minute) and resuspended in 340 mL proteinase-K buffer (10 mmol/ detection. The same analysis was extended to 51 additional unrelated
normal subjects.L Tris-HCl, pH 7.6; 10 mmol/L EDTA, pH 8; 50 mmol/L NaCl),
Cloning and sequencing of the RT-PCR FAS product. The PCR30 mL 10% sodium dodecyl sulfate (SDS) and 30 mL proteinase-K
product was ligated to a pCRII vector (TA Cloning Kit; Invitrogen(20 mg/mL) and then incubated at 567C for 30 minutes; after the
Corp, San Diego, CA). Plasmids were grown in INVaF* modifiedaddition of 200 mL saturated Na-acetate, the sample was shaken
competent Escherichia coli cells in LB agar plates, and singlevigorously for 15 seconds; precipitated proteins were spun down
plaques were picked up and expanded according to the manufactur-(13,000 rpm, 5 minutes); 600 mL isopropyl alcohol was added to
er’s instructions (TA Cloning Kit). To verify the presence of thethe supernatant; the precipitated DNA was washed once with 70%
correct insert, recombinant plaques were tested by PCR with theethanol at room temperature, and finally dissolved in H2O.
previously described primers. Positive plaques were selected, andPreparation of RNA, cDNA synthesis, and amplification of cDNA
plasmid DNA was purified using QIAwell 8 Plasmid Kit (Qiagen)by polymerase chain reaction (PCR). Total RNA was prepared by
and sequenced with an Automated Laser Fluorescent A.L.F. DNAthe guanidinium thiocianate-phenol–chloroform method from
Sequencer (Pharmacia LKB, Uppsala, Sweden) using the AutoReadPBMC of the patients. One microgram of RNA was used to synthe-
Sequencing Kit (Pharmacia). In the case of FAS cDNA clones, bothsize the first strand of the FAS chain-specific complementary DNA
universal and reverse primers were used.(cDNA) using the RiboClone cDNA Synthesis System (Promega
Corp, Madison, WI) and a Fas-specific primer ( 5* CTA GAC CAA
GCT TTG GAT TTC 3*). The cDNA reaction mixture was then RESULTS
subjected to enzymatic amplification using the following Fas forward
Lymphocyte surface marker analysis. Immunopheno-and reverse primers (5* ACG TGA TTC ATG TTG GGC ATC TGG
type of the PBL (Table 2) showed that all three siblings hadACC CTC CTA 3*; 5* ACG TAA GCT TAC TAG TAA TGT CCT
an expansion of CD3/CD40CD80 cells. Among CD40CD80TGA GG 3*), which was designed to amplify the functional gene.
The original sequences of these primers were modified respectively T cells, a sizeable proportion was represented by TCRAB/
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Table 2. Main Immunological Features
Patient Patient Patient Normal Values
Surface Markers M.F. N.F. S.F. Mother Father (mean { SD)
Immunophenotypical analysis (%)
CD2 84 91 84 ND ND 80 { 6
CD3 73 88 80 81 75 71 { 7
CD4 13 28 30 45 57 40 { 7
CD8 42 37 26 35 16 25 { 5
CD16 9 6 7 ND ND 11 { 5
CD19 13 11 12 ND ND 18 { 6
HLA-DR 41 23 25 ND ND 20 { 8
CD40 CD80 among CD3/ 30 21 26 2 3 5
TCRAB/ among CD40 CD80 41 45 37 1 1 3
HLA-DR/ among CD3/ 33 19 18 ND ND 10
CD2/ among CD3/ 97 98 95 ND ND 95
CD280 among CD4/ 12 15 3 3 3 5
CD280 among CD8/ CD3/ 76 68 57 40 44 41 { 14
Patient M.F. (PBMC) Patient M.F. (CD40 CD80 PBMC) Healthy control (PBMC)
Proliferative response
Medium 190 { 9 800 { 95 2,200 { 140
PHA (1.2 mg/mL) 35,550 { 1,050 4,100 { 35 51,500 { 3,200
CD3 (200 ng/mL) 46,500 { 270 2,000 { 12 61,550 { 1,600
CD3 (200 ng/mL) /
IL2 (20 U/mL) 64,050 { 680 7,350 { 7 74,600 { 920
SEB (500 ng/mL) 30,150 { 920 1,600 { 52 57,700 { 920
Proliferation studies of M.F. patients’ total and CD3/ CD40 CD80 enriched PBMC. Data are expressed as the mean cpm { SEM of a triplicate
culture. Similar results were obtained for patients N.F. and S.F. (data not shown).
Abbreviation: ND, not determined.
cells, a subset that is usually negligible in normal controls. doses of PMA and ionomycin failed to induce CD40L, but
resulted in normal expression of the activation marker CD69.In addition, all CD3/ lymphocytes were also CD2/ and a
We performed analysis of the TCRBV repertoire of DNsubstantial proportion of them expressed the activation
versus SP T cells in the affected sibling M.F., who showedmarker DR. Finally, an increased proportion of CD280 cells
the most prominent signs of lymphadenopathy and spleno-were found both among CD4/ and CD8/ T lymphocytes.
megaly. No bias in the usage of the TCRBV rearrangementsThe distribution of NK (CD16/) and B (CD19/) lympho-
was identified in any cell subpopulation, arguing againstcytes did not differ from normal controls.
preferential expansion of T-cell clones in response to specificOn the contrary, no immunophenotypical abnormalities (ie,
antigens (data not shown).presence of ‘‘double negative’’ cells or expansion of
Functional analysis of Fas-induced apoptosis. The dem-CD3/CD280 cells) were found on PBL of parents (Table 2).
Serum levels of soluble activation markers. In keeping with onstration of an expanded subset of DN T cells that were
the demonstration of an increased proportion of activated anergic to common in vitro stimuli prompted us to investi-
(HLA-DR/) peripheral blood T lymphocytes, increased levels gate the possibility of a Fas defect in the family.
of serum sIL-2R were found in the patients (M.F.: 7,155 U/ As shown in Fig 3 for monoclonal CH11, upon in vitro
mL; N.F.: 1,989 U/mL; S.F.: 2,154 U/mL), as opposed to the stimulation with PHA, PBMC from patients expressed the
parents (father: 803 U/mL; mother: 391 U/mL) and normal Fas molecule at the cell surface, but the intensity of staining
controls (mean { SD: 526{ 103 U/mL; n 8). Similar results was consistently slightly reduced as compared with the par-
were obtained when serum levels of sCD30 were analyzed: in ents. Fas expression in activated PBMC from both parents
fact, higher levels were found in the patients (M.F.: 251 U/ was comparable to that observed in controls (data not
mL; N.F.: 59 U/mL; S.F.: 37 U/mL), as compared with the shown). Similar results were produced with all anti-CD95
parents (father: 11 U/mL; mother: 17 U/mL) and normal con- MoAb tested (data not shown).
trols (mean { SD: 11 { 9 U/mL; n  8). In addition, defective apoptosis through cross-linking of the
Immunological features of ‘‘double negative’’ T cells. Fas antigen was demonstrated in the affected siblings. In fact,
Analysis of in vitro lymphocyte proliferation showed that as shown in Fig 4A, where the lymphocytes were stimulated
PBMC from all three siblings mounted a normal proliferation with PHA for 2 days and IL-2 for 5 days, addition of various
to various stimuli (Table 2). In contrast, the enriched concentrations of CH11 antibody (which is known to deliver
CD3/CD40CD80 population were unresponsive to PHA, death signals through cross-linking of the Fas antigen) failed
anti-CD3, and SEB. Addition of exogenous IL-2 slightly to result in AICD in the three siblings. In contrast, under the
increased the proliferative capacity in response to CD3. same conditions, a comparable apoptosis was described in the
two parents and in a series of normal controls.As shown in Fig 2, stimulation of DN T cells with optimal
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 For personal use only. by on August 7, 2008. www.bloodjournal.orgFrom 
BETTINARDI ET AL906
apoptosis despite preservation of Fas molecule expression.
All three affected siblings inherited one mutated Fas allele
from each heterozygous parent. Neither parent showed
any immunological abnormalities (including Fas-mediated
apoptosis), nor did they ever develop clinical signs of the
Fig 2. Expression of CD40L and CD69 on single positive (SP) T
cells and on CD3"CD4ÏCD8Ï (DN) enriched PBMC of patient M.F. The
cells were activated with PMA (5 ng/mL) " ionomycin (500 ng/mL)
for 16 hours. Dashed lines represent the fluorescence of cells stained
with nonimmune mouse IgG. Data are presented as relative log fluo-
rescence intensity.
Finally, as shown in Fig 4B, the lymphocytes from all
patients demonstrated intact apoptotic response when stimu-
lated with dexamethasone, thus indicating that the cells of
the patients were not intrinsically resistant to AICD.
Molecular analysis of Fas defect. Search for mutations
in the Fas gene was accomplished by reverse transcriptase
(RT)-PCR, cloning, and sequencing. As shown in Fig 5A,
all three siblings were found to carry two distinct mutations,
each of which was inherited from one of the parents.
In particular, the maternally-derived mutated allele carried
a C to T mutation at nt 555, as compared with the wild-
type cDNA sequence,23-25 which results in a tryptophane for
arginine substitution at codon 105 in the second cystein-
rich–homology (CRH) domain at the extracellular side of
the protein. This mutation was confirmed at the genomic
level by restriction analysis. In fact, the C to T mutation
abolishes a restriction site for the HpaII enzyme. Genomic
DNA amplification in the region encompassing nt 030 of
intron three and nt /30 of intron four, followed by digestion
with HpaII, generates two fragments of 113 and 56 bp. As
expected, both in the patients and in their mother, an aberrant
band of 169 bp was identified, in addition to the wild-type
fragments of 113 and 56 bp, thus confirming heterozygosity
for the mutation (data not shown). A similar analysis was
applied to 51 normal individuals, none of whom showed the
aberrant 169-bp band, thus also ruling out the possibility
that the C to T change at nt 555 represents a polymorphism
(data not shown).
The paternally derived mutant allele caused an A to G
substitution at nt 889, resulting in a tyrosine to cysteine
mutation at codon 216 at the N-terminus of the death domain
in the intracytoplasmic region of the molecule. This mutation
falls in a region conserved between human and murine Fas
proteins (Fig 5B).
Fig 3. CD95 expression on PBMC from patients and their parents.
Cells were activated with PHA (1.2 mg/mL) for 72 hours. Dashed linesDISCUSSION
represent the fluorescence of cells stained with nonimmune mouse
We have reported a novel family with ALPS due to muta- IgG. Data are presented as relative log fluorescence intensity. Data
are representative of two independent determinations.tions in the Fas gene resulting in lack of Fas-induced
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Fig 4. (A) Defective Fas-mediated apoptosis of patients’ lymphocytes (s, M.F.; h, N.F.; n, S.F.) as compared with normal induction of
apoptosis on lymphocytes from parents (l, father; j, mother) and five healthy controls (m). Cells were activated with PHA (1.2 mg/mL) for 2
days and IL-2 (20 U/mL) for 5 days and then incubated for 24 hours with or without various concentrations of an anti-Fas antibody known to
deliver an apoptotic signal (CH11). The percentage of apoptotic cells as a function of the CH11 antibody concentration is shown. For healthy
controls, data are expressed as mean Ô 1 SD. One representative experiment of three is shown. (B) Normal dexamethasone-induced apoptosis
of lymphocytes from all affected siblings as compared with their parents and three healthy controls. Cells were activated with PHA (1.2 mg/
mL) for 2 days and IL-2 (20 U/mL) for 5 days and then incubated for 24 hours with or without dexamethasone 10-5 mol/L. The percentage of
apoptotic cells is shown.
disease; furthermore, extensive family history failed to show The maternally-inherited mutation resulted in the substitu-
tion of neutral tryptophane for the cationic arginine on theadenopathy, splenomegaly, or autoimmunity in any other
relatives. Based on these findings, a typical autosomal reces- extracellular side of the protein, in the CRH2 domain. Al-
though none of the reported Fas-gene polymorphisms leadsive pattern of inheritance can be argued. This is similar to
what was observed in MRL-lpr/lpr mice, but contrasts with to amino acid substitution,26 the possibility that this noncon-
servative amino acid change represents a polymorphism wasmost ALPS families due to Fas defects so far reported in
humans, in which occurrence of a pathological phenotype, ruled out, as no evidence for the same nucleotide substitution
was obtained by PCR and restriction analysis in 51 normaldespite heterozygosity for Fas mutations, was explained by
a dominant negative effect,17 or possibly by a digenic inheri- subjects. For the paternally-derived mutation, although tyro-
sine 216 lies N-terminal to the Fas death domain, and itstance, with concurrent effect of a yet undefined apoptosis
defect inherited from the parent with no mutations in the mutation to cysteine should not, therefore, directly affect
the function of this motif, it is conserved in the murineFas gene.
In the present family, simultaneous occurrence of mis- homologue,24,27 suggesting structural or functional con-
straints. None of the two mutations alone substantially af-sense mutations on both Fas gene alleles was reported to
result in defective apoptosis and aberrant clinical features. fects Fas expression or function, since heterozygous parents
Fig 5. (A) Mutation analysis
in the Fas gene. Sequence analy-
sis performed with the Auto-
mated Laser Fluorescent A.L.F.
DNA Sequencer on amplified ge-
nomic fragments encompassing
nt 543-569 and nt 876-902 of the
Fas cDNA is shown. (B) Se-
quence of human and murine
Fas cDNA at the N-terminus of
the death domain. The con-
served amino acids are boxed.
The arrow indicates the tyrosine
that is mutated to cysteine in the
three affected siblings and in
their father.
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were comparable to controls. It is conceivable that depending expression of the early activation antigen CD69 was ob-
served.on the severity of Fas gene mutations, Fas defect may follow
a single autosomal recessive inheritance (as in the present Finally, we have demonstrated an increased proportion of
CD280 cells among SP CD4 or CD8 T lymphocytes. Be-case) or result from a dominant-negative effect, particularly
when expression of mutant Fas protein strongly interferes cause CD28 costimulation is known to enhance expression
of Bcl-xL,43 and thus contribute to prolonged T-cell survival,with either Fas trimer expression or function.
Although little data are available on the CD95 epitopes downregulation of CD28 expression in SP T cells from pa-
tients with Fas defect may represent an additional mecha-recognized by the MoAbs used in this study, the demonstra-
tion that a reduced expression of CD95 was consistently nism for homeostatic control of terminally differentiated T
cells that may not undergo Fas-mediated apoptosis.observed in the three affected siblings with all CD95 mono-
clonals, is in favor of a reduced density of CD95 molecules
at the cell surface rather than of a single conformational ACKNOWLEDGMENT
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